ovarian
No description yet: the sentence for this tag has not been written. 12 records carry it: 12 people.
Related tags
12 records
| Cancers | Other tags | ||||
|---|---|---|---|---|---|
Andreas du Bois Director of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte; Chair, AGO Study Group · Kliniken Essen-Mitte Surgeon who chairs the German AGO group and led DESKTOP III, proving secondary surgery can extend survival in selected relapsed ovarian cancer. | Ovarian cancer | none | surgery, cooperative-group | ||
Bradley J. Monk Gynecologic Oncologist, Florida Cancer Specialists; Professor, University of Arizona and Creighton University; Co-Director, GOG Partners Gynaecologic oncologist who co-led KEYNOTE-826, innovaTV 301 and KEYNOTE-A18, the trials that rebuilt cervical cancer treatment. | Cervical cancer, Ovarian cancer | none | cervical, cooperative-group | ||
David M. Gershenson Gynaecologic oncologist, MD Anderson Cancer Center · MD Anderson Cancer Center Houston gynaecologic oncologist who defined low-grade serous ovarian cancer as a distinct disease and led GOG 281, the trial that showed the MEK inhibitor trametinib works better than standard treatments for it. | Low-grade serous ovarian cancer, Ovarian cancer | none | gynaecological, trialist | ||
Ignace Vergote Emeritus Professor of Gynaecologic Oncology, University Hospitals Leuven; Chair, BGOG and ENGOT · UZ Leuven / Leuven Cancer Institute Led the EORTC trial that made neoadjuvant chemotherapy acceptable in ovarian cancer and innovaTV 301, the first ADC survival win in cervical cancer. | Ovarian cancer, Cervical cancer | none | cervical, adc, cooperative-group | ||
Isabelle Ray-Coquard Professor of Medical Oncology, Centre Léon Bérard and Université Claude Bernard Lyon 1; President, GINECO · Centre Léon Bérard Led PAOLA-1, which showed olaparib plus bevacizumab helps women with HRD-positive ovarian cancer beyond BRCA carriers. | Ovarian cancer | none | parp, hrd | ||
Jonathan A. Ledermann Professor of Medical Oncology, UCL Cancer Institute; Consultant, UCLH · University College London Hospitals / UCL Cancer Institute Led Study 19, the trial that first showed PARP inhibitor maintenance works in ovarian cancer. | Ovarian cancer | none | parp, uk | ||
Kathleen N. Moore Associate Director of Clinical Research, Stephenson Cancer Center, University of Oklahoma · Stephenson Cancer Center, OU Health Led SOLO-1 and MIRASOL, which gave ovarian cancer a maintenance PARP inhibitor and its first ADC with a survival benefit. | Ovarian cancer | none | parp, adc, trialist | ||
Mansoor Raza Mirza Chief Oncologist, Rigshospitalet, Copenhagen University Hospital; Chair, ENGOT · Rigshospitalet, Copenhagen University Hospital Led NOVA and RUBY, the trials that established niraparib maintenance in ovarian cancer and dostarlimab in advanced endometrial cancer. | Endometrial cancer, Ovarian cancer | none | endometrial, trialist | ||
Robert L. Coleman Chief Scientific Officer, US Oncology Research; Gynecologic Oncologist, Texas Oncology · The US Oncology Network / US Oncology Research Gynaecologic oncologist who led ARIEL3 and GOG-0213, shaping PARP maintenance and secondary surgery in relapsed ovarian cancer. | Ovarian cancer | none | parp, surgery | ||
Susana Banerjee Consultant medical oncologist, The Royal Marsden and The Institute of Cancer Research · The Royal Marsden London gynaecological oncologist who led RAMP 201, the trial that established the avutometinib and defactinib combination for recurrent KRAS-mutant low-grade serous ovarian cancer. | Low-grade serous ovarian cancer, Ovarian cancer | none | gynaecological, targeted-therapy, trialist | ||
Usha Menon Professor of Gynaecological Cancer, MRC Clinical Trials Unit at UCL · University College London Hospitals / UCL Cancer Institute Led UKCTOCS, the 200,000-woman trial that found ovarian cancer screening does not save lives despite detecting cancers earlier. | Ovarian cancer | none | screening, early-detection | ||
Willemien J. van Driel Gynaecologic Oncologist, Netherlands Cancer Institute · Netherlands Cancer Institute (NKI-AvL) Led OVHIPEC-1, the trial that showed heated intraperitoneal chemotherapy at surgery extends survival in ovarian cancer. | Ovarian cancer | none | surgery, hipec |
